En Carta Diagnostics
En Carta Diagnostics is a synthetic-biology biotech company leveraging patented technologies to decentralise highly reliable molecular diagnostic solutions.
En Carta Diagnostics has raised €6.5M across 2 funding rounds from 7 investors, most recently a round in Jul 2026. Based in Paris, France; active in Healthtech. Data as of 28 Oct 2026.
Paris, Francewww.encarta.bio ↗
Total raised
€6.5M
€6,500,000
Funding rounds
2
Investors
7
distinct backers
Active since
2024-05
latest 2026-07
Funding by year
EUR raised per year · 2026 YTDEn Carta Diagnostics — funding by year — interactive chart.
Data table
| En Carta Diagnostics — funding by year | |
|---|---|
| 2024 | €1.5M |
| 2026 | €5.0M |
Signals
High confidenceRaise-next likelihood20
base rate 30% for Other
- ▼ Raised very recently
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood13
base rate 11% (2+ rounds)
- ▼ Young (<3y)
- ▲ Recently backed by strong-exit-track investors
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-07-10 | Other | €5.0M | 50 Partners Health,Blue Forest Ventures,Bpifrance,Business Angels,CentraleSupélec Venture,other partners+1 more | View deal → |
| 2024-05-23 | Other | €1.5M | Business Angels,CentraleSupélec Venture | View deal → |
Investors
7Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData